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Abstract: Selective targeting of transfected mesenchymal stem cells (MSCs) carrying specific antioncogenes to the tumor was suggested
as a treatment option. Bone morphogenetic protein-2 (BMP2) was shown to inhibit the proliferation and aggressiveness of osteosarcoma
(OS) cells. Here, we aimed to assess the homing efficiency of intraperitoneally administered hMSCs transfected with BMP2 to the
tumoral site and their effects on OS using an orthotopic xenograft murine model. Orthotopic xenograft murine model of OS in sixweek-old female NOD/SCID mice using 143B cells was established. hMSCs transfected with BMP2 (BMP2+hMSC) were used. In vivo
experiments performed on four groups of mice that received no treatment, or intraperitoneally administered BMP2, hMSCs, and
BMP2+hMSCs. Histopathological and immunohistochemical studies were used to evaluate the pathological identification and to assess
the dimensions and necrotic foci of the tumor, the features of lung metastases, and immunostaining against p27, Ki-67, and caspase-3
antibodies. The osteogenic differentiation markers BMP2, BMP4, COL1A1, OPN, OCN and PF4 evaluated using RT-PCR. The tumor
dimensions in the hMSCs group were significantly higher than those of the remaining groups (p < 0.01). The number of metastatic
foci in the BMP2+hMSCs group was significantly lower than those of the other groups (p < 0.01). The current results showed that the
intraperitoneal route could be efficiently used for targeting hMSCs to the tumoral tissues for effective BMP2 delivery. In this study, the
effects of BMP2 transfected hMSCs on human OS and metastasis were promising for achieving osteogenic differentiation and reduced
metastatic process.
Key words: Intraperitoneal, BMP2, tumor, lung metastasis, osteogenic differentiation, targeting

1. Introduction
Osteosarcoma (OS), the most common sarcoma of bone,
which is characterized by osteoid and bone production by
malignant spindle cells, usually occurs at the metaphyseal
regions of the long bones with a high osteoblastic activity
and populated with rapidly dividing mesenchymal cells
and preosteoblasts (Aydin et al., 2015; Fan et al., 2020).
Mesenchymal stem cells (MSCs) capable of self-renewal,
proliferation, and differentiation give rise to osteoblasts
within a sophisticated network of genes and factors that
play distinct roles in complex signaling pathways. MSCs
can secrete various paracrine factors interacting with
other cells, and they can selectively target specific areas in

the body. These characteristics seem very promising in the
treatment of disorders like stroke, myocardial infarction,
and various malignant tumors (Luo et al., 2008).
The osteogenic differentiation pathway is coordinated
by various growth and differentiation factors (Rutkovskiy
et al., 2016). Bone morphogenetic proteins (BMPs),
Runx2, collagen type 1 alpha 1 (COL1A1), osteocalcin
(OCN), and osteopontin (OPN) are among the factors
that pave the road from proliferation to differentiation of
MSC towards an osteocyte (Luo et al., 2008; Rutkovskiy et
al., 2016). The invariable presence of an osteoid matrix in
tumor tissue is evidence for terminal differentiation defect
of osteoblasts in the pathogenesis of OS, which occurs
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when osteoblasts survive despite any disturbance during
the differentiation phase of osteogenesis (Luo et al., 2008).
Although classified as a rare tumor type, the five-year
survival rate of OS is 20% in adolescents, and mortality is
frequently due to lung metastasis (Fan et al., 2020).
Target-selective treatments for increasing survival
and decreasing side effects of conventional therapies have
been the focus of recent studies. Advances in genetic
engineering have enabled the potential use of stem cellbased therapeutics as a promising option in OS (Chindamo
et al., 2020). The specific features inherent to human MSCs
(hMSCs) encouraged researchers to investigate ways of
their therapeutic applications. The selective targeting of
transfected MSCs with specific antioncogenic factors to
the tumor site was suggested to be an effective treatment
option (NguyenThai et al., 2015).
As members of the transforming growth factor-β
(TGF-β) protein superfamily, BMPs participate in a
variety of biological processes, like angiogenesis and tissue
fibrosis. With such diversity of functions, BMPs have
gained immediate interest for therapeutic use in tissue
engineering and biomedical regenerative therapies. On top
of all, there are some studies that investigated the use of
BMP2 in the treatment of oncologic conditions (Xiong et
al., 2018). For example, exogenous BMP2 administration
had been shown to inhibit the proliferation and aggressive
properties of human colorectal cancer cells (Zhang et al.,
2014). On the contrary, BMP2 has recently been shown
to promote the growth of cells of the 143B OS line and
enhance their mobility and invasiveness, suggestively
through Wnt/beta-catenin signaling pathway (Tian et al.,
2019).
The interactions among OS and hMSCs in the presence
of BMP2 were explored by the degree of differentiation
of tumoral cells using osteogenic markers like COL1A1,
OPN, and OCN that are sequentially expressed matching
the temporal pattern of osteoblastic differentiation
(Edgar et al., 2007). While COL1A1 appears as an early
differentiation marker, OPN peaks in dual-mode during
the proliferation and end-proliferation stages, and OCN
emerges as a late marker of differentiation (Huang et
al., 2007). OPN, which is a late marker of osteogenic
differentiation and a phosphoprotein involved in the
proliferative, migrative, and adhesive properties of hMSCs
in a bidirectional way, is expressed in significantly lower
amounts in OS cells compared to differentiated mature
osteoblasts (Si et al., 2020). The expression of OCN
elevates with the transformation of preosteoblasts to fully
differentiated osteoblasts (Miron and Zhang, 2012). Some
cytokines like BMP2 and BMP4 modulate the osteoblastic
differentiation process with a temporal expression pattern,
i.e. earlier, and gradually diminishing expression of BMP4
and later and more constant expression of BMP2 (Edgar
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et al., 2007; Huang et al., 2007). The expression of BMP4
was shown to induce MSCs towards osteogenic lineage
(Wright et al., 2002). In the osteoblast-differentiated MSC
cell line Ost-B10, the osteoblastic differentiation had been
associated with increased levels of platelet factor 4 (PF4),
which is a factor in blood coagulation and modulator of
cellular migration (Mishima et al., 2010).
The only conclusion that could be safely drawn from
the current literature is the unavailability of consistency
among results of studies on the efficiency and the safety
of using BMP2 and hMSCs together or separately in OS
treatment. Overall, the effect of MSCs from different
origins that were transfected with various BMP types on
OS has been investigated in a number of experimental
studies in animals, while there are no such studies in
human OS tissue to the best of our knowledge (Thawani
et al., 2010; NguyanThai et al., 2015; Qiao et al., 2015; Tian
et al., 2019). In this study, we aimed to assess the homing
efficiency of intraperitoneally administered hMSCs
transfected with BMP2 and their effects on human OS and
lung metastasis in vitro and in vivo experiments using an
orthotopic xenograft murine model.
2. Materials and methods
2.1. Study design
This study was conducted in the Department of
Orthopedics, Faculty of Medicine, Başkent University,
designed to consist of in vitro and in vivo experiments. All
animal experiments complied with the Animal Research:
Reporting of in vivo Experiments version 2.0 (The ARRIVE
guidelines 2.0) and have been carried out according to the
Institutional Ethics Committee Regulations and National
Institutes of Health guide for the care and use of Laboratory
Animals (NIH Publications No.9-8023, revised 1978).
2.2. Cell lines and experimental animals
The animals were housed at 20–22 ºC with 12 h light/
dark cycle. The human OS cell line, 143B, was purchased
from the American Type Culture Collection (ATCC;
CRL-8303). The human bone marrow MSC line defined
previously (Karaöz et al., 2011) used from institutional cell
bank. Cell culture reagents were purchased from Thermo
Fisher Scientific (Paisley, UK) unless noted otherwise.
2.3. Cell cultures and hMSCs labeling with green fluorescent protein (GFP)
The culture conditions for 143B and hMSCs lines were
adjusted according to previous works (Karaöz et al.,
2011; Garimella et al., 2017). Mycoplasma contamination
was tested using a PCR-based kit (EZ-PCR Mycoplasma
Detection Kit, #20-700-20, Biological Industries, BeitHaemek, Israel), and subculturing was performed when
70%–80% confluency was achieved. The hMSCs at
passage 4 were labeled with GFP (designated as hMSCs
for simplification), as described previously (Adas et al.,
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2016). For the cell labeling, pAcGFP-N1vector (Clontech,
Mountain View, CA, USA) was transfected using Neon
Transfection System (Invitrogen, Life Technologies,
Carlsbad, CA, USA) with the previously optimized settings
of 990 V, 20 ms and 2 pulses.
2.4. hMSCs transfection with GFP and BMP2
Escherichia Coli (E. coli) (NEB 5-alpha, #C2987I, New
England BioLabs, Frankfurt, Germany, GeneBank/
EMBL accession #Y14837) was propagated in LB
supplied with 15 g/L agar, 10 g/L Tryptone, 5 g/L yeast
extract, and 0.5 g NaCl at 37 ºC. Human BMP2 gene
(NM_001200.2) was purchased on pUC57 (2710 bp,
#SD1176, GenScript, Piscataway, Township, NJ, USA).
After the subcloning, the vector with BMP2 gene was
purified with Fast Plasmid Mini Kit (5PRIME, Hamburg,
Germany). The amplification of the BMP2 fragment
with proper restriction enzyme sites was performed in
PCR Thermal Cycler Dice (Takara, Tokyo, Japan) using
Phusion High-Fidelity DNA polymerase (#F530S, Thermo
Fisher Scientific, Leon-Rot, Germany) using the primer
pairs F:5’-GGATCCATGGTAGCCGGGAC-3’ and R:5’GGATCCTAGCGACACCCACAACC at Tm = 58 ºC. The
amplified fragments were purified from the PCR reactionby
PCR Agarose Gel Extract Mini Kit (5PRIME). BamHI
restriction enzyme (#ER0051, Fermentas, Thermo Fisher
Scientific, Vilnius, Lithuania) was used to digest both
the amplified BMP2 fragment and the expression vector
(pFLAG-CMV™-3, #E6783, Sigma-Aldrich, St. Louis, MO,
USA). T4 DNA ligase (#EL0014, Thermo Fisher Scientific,
Vilnius, Lithuania) was used to ligate the BMP2 fragment
adjacent to the signal peptide sequence of the vector. E.
coli was transfected with the constructed plasmid and
allowed to propagate in LB under selective conditions
against Kanamycin (35 mg/dL, Merck, Darmstadt,
Germany). After purification of BMP2 plasmid from E.
coli cells, PicoDrop spectrophotometer (Picodrop Limited,
Saffron, Walden, UK) at 260 nm wavelength was used for
estimating the concentration of the product. The size of the
BMP2 fragment on pFLAG-CMV-3-BMP2 was verified by
PCR. Electroporation by Neon Transfection System was
used for the cotransfection of hMSCs at passage 4 with
0.7 µg pAcGFP-N1 and 4 µg pFLAG-CMV-3-BMP2 (6:1,
mol/mol), and under selective condition of 0.2 mM G418
(Thermo Fisher Scientific, Gibco), hMSCs expressing both
GFP and BMP2 were obtained. For simplification, this cell
line was designated as BMP+hMSCs.
2.5. Coculture of 143B and BMP2+hMSCs cell lines
143B cells were cultured on a 6-well plate (3 × 104 cells/
well) for 24 h. hMSCs or BMP2+hMSCs (both 3 × 104
cells/well) cultured for 24 h on 1 µm permeable wells
(#353102, Falcon, BD Biosciences, Bedford, MA, USA)
were seeded on permeable insert (3 µm, #353091, Falcon,
BD Biosciences) for coculturing for 48 h.

2.6. Detection of BMP2 protein levels in cultures using
ELISA
The BMP2 levels in hMSCs and BMP2+hMSCs cultures, and
143B+hMSCs and 143B+BMP2+hMSCs cocultures were
measured (×3 for each sample) in the 4th and 14th culture
days using human BMP2 ELISA kit (#EK0311, Boster,
Pleasanton, CA, USA) according to the manufacturer’s
instructions. After 2 days of culture in DMEM, 500 µL of
culture medium was used to analyze the level of secreted
BMP2 level.
2.7. Orthotopic xenograft murine model of human OS
The Institutional Animal Care and Use Committee and
Ethical Committee of Kobay DHL A.Ş. approved the study
protocol (Approval date 05.03.2013 and approval number
61). Six-week-old female nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice (Jackson
Laboratory, Bar Harbor, ME, USA) used for orthotopic
xenograft transplantation were housed under previously
defined conditions. The left proximal tibia of all mice was
injected with 1 × 106 143B cells suspended in 50 µL (2 ×
107 cells/mL) on Day 0, in the phosphate-buffered saline
(PBS) (SIGMA, Cat No: 806552) as described (Luu et al.,
2005; Luo et al., 2008).
The mice were divided into four groups. Group 1
(n = 12) (control) received no additional treatment.
Group 2 (n = 14), group 3 (n=12), and group 4 (n=12)
received intraperitoneal administration of 100 mcg/
day BMP2 protein (catalog number: 34-8507-85) (14th
and 21st days), 1 × 106/75 µL hMSCs (14th day), and 1 ×
106/75 µL BMP2+hMSCs (14th day), respectively. Excess
pentobarbital on the 28th day was administered to sacrifice,
and the lungs and lower extremities were harvested.
2.8. Histopathological and immunohistochemical studies and gene expression analysis
The size of the tumor was measured as the maximum length
of tibia covered by tumoral mass. The differentiation and
necrosis in tumor tissue and the number and localization of
lung metastases were evaluated in at least six representative
sections from each mouse. The degree of tumor necrosis
was graded by the ratio of necrotic area to the whole tumor
tissue and scored as 1(+) when ≤ 25%, 2(+) when 26%–
50%, 3(+) when 51%–75%, and 4(+) when ≥ 75%.
The tissue sections from the tibia and lungs were fixed
in 10% formaldehyde and embedded in paraffin blocks.
Deparaffinized 4–5 µm sections were mounted on a single
slide and stained with hematoxylin and eosin (H+E) for
light microscopy examination. For immunohistochemical
studies, deparaffinized sections were mounted on polyl-lysine pretreated membrane slides. The proliferation,
differentiation, necrosis, and apoptotic indices of tumor
tissue were determined by Ki-67, p27, and caspase-3
immunohistochemical staining. The OS and lung tissues,
as well as bronchial epithelial cells of mouse in addition
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to human tonsil tissue, were used as positive controls in
immunohistochemical studies. The mouse periosteal callus
tissue from healing femur fracture was used as the positive
control for BMP2, and multiple experiments with various
dilutions and durations were performed to determine the
strongest positivity of osteoblasts against BMP2 antibody
for reference in determining the staining intensity scoring.
Standard conditions for streptavidin-biotin peroxidase
staining were used for immunohistochemical staining. The
primary antibodies used in immunohistochemical studies
were presented in Table 1. The immunohistochemical
evaluations and scoring were performed by a single
pathologist. For BMP2 scoring, cytoplasmic staining
intensity was assessed, while p27 scoring was assessed
separately by the ratio and intensity of positive cells to the
whole tumor area and estimation of cumulative staining
score (from 1 to 12) by the product of the two scores.
For the Ki-67 proliferation index, a total of 1000 cells
from the most intense regions under ×400 magnification
were counted to estimate the ratio of positive cells. The
most intense or wider extent of cytoplasmic staining was
assessed for caspase-3 scoring.
For the gene expression analysis, the samples were cut
in small pieces and homogenized in phosphate buffered
saline (PBS, pH 7.4, Thermo Fisher Scientific) by syringe
with 26G needle and total RNA was isolated by total RNA
isolation kit (Jena Bioscience, Jena, Germany), according
to the protocol provided by the manufacturer. Four
hundred microliters lysis solution with β-mercaptoethanol
was added and vortexed for 15 s. Then, the samples were
transferred to filtered tubes and centrifuged in 8000 g for

15 s. The filtered samples were treated with 40 U DNase
and incubated at room temperature for 25 min. The
samples were twice washed with 500 µL washing buffer
provided within the kit and centrifuged in 8000 g for 15 s.
Next, the tubes were centrifuged in 13,000 g for 60 s, RNA
in the filters were eluted by RNase/DNase free distilled
water and centrifuged in 10,000 g for 2 min. Then, filtered
tubes were removed, and the remaining samples were
placed on ice. The concentration of RNA was measured
in 260 nm wavelength using PicoDrop spectrophotometer.
Finally, a total of 1 µg isolated RNA was used to synthesize
cDNA using Transcriptor High Fidelity cDNA Synthesis
Kit (Roche, #5081955001) according to the manufacturer’s
protocol.
Real-time PCR using Power SYBR Master Mix
(Invitrogen, Applied Biosystems, CA, USA) in LightCycler
480-II (Roche) was performed for studying the expressions
of GFP, BMP2, BMP4, COL1A1, OCN, OPN and PF4 genes.
The primer sequences were given in Table 2. Relative
quantification was determined by second derivative
method performed using LightCycler 480 software 1.5
(Roche). Fold expression was calculated by ΔΔCP method
with normalization to beta Actin (ActB) housekeeping
gene.
2.9. Statistical analysis
The assessment of data distribution was made by visual
(histogram and probability tables) and analytic methods
(Kolmogorov–Smirnov/Shapiro–Wilk’s test). Median and
interquartile range (IQR) were determined according to
the variable distributions in definitive analysis. Data were

Table 1. Primary antibodies used in immunohistochemical studies.
Protein

Antibody

Company

Clone/lot

IHC working condition

Bone morphogenetic protein 2 BMP-2

LifeSpan BioSciences

LS-B12549 1:100

Caspase-3

Caspase-3

Atlas Antibodies

A36181

p27 Kip1

p27

DAKO

M720301

Ki-67 (MIB 1)

Ki-67 (MIB-1) Thermo Fisher Scientific IR626

1:200
1:50
Ready to use

Table 2. Primer sequences used in RT-PCR.
Protein
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Forward primer

Reverse primer

Bone morphogenic protein 2 BMP2

Gene

ACCCGCTGTCTTCTAGTGTTG

TTCTTCGTGATGGAAGCTGAG

Bone morphogenic protein 4 BMP4

ACTTCGAGGCGACACTTCTG

GTCCACCTGCTCCCGAAATA

Collagen type 1, alpha 1

COL1A1 AAGAGGAAGGCCAAGTCGAG

TAAGACAGCTGGGGAGCAAA

Osteocalcin (BGLAP)

OCN

CCTGACTGCATTCTGCCTCT

TCGTCACAATTGGGGTTGAG

Osteopontin (SPP1)

OPN

CCGATGAATCTGATGAGTCCTT TCCAGCTGACTTGACTCATGG

Platelet factor 4 (CXCL4)

PF4

AGCCCTGAGCTGCTTCTTCT

TCCTGCTTTGATCACCTCCA

Actin, beta

ActB

TTCTACAATGAGCTGCGTGTG

GGGGTGTTGAAGGTCTCAAA

SARI et al. / Turk J Biol
analyzed using the Kruskal–Wallis and Wilcoxon matchedpairs signed-ranks test. The differences among groups were
analyzed by the Mann–Whitney U test using Bonferroni
correction. SPSS v. 21. for Windows (IBM Corporation,
Armonk, NY, USA) was used for all statistical analyses,
and a p-value below 0.05 was considered statistically
significant.

500–510 nm wavelength. To generate BMP2 expressing
mesenchymal stem cells, hMSCs were cotransfected with
GFP and BMP2 (BMP2+hMSCs) and were observed under
fluorescent microscopy after the selective culture for G418
resistance (Figures 1c and 1d). RT-PCR results revealed
constitutive BMP2 expression in BMP2+hMSCs in the 2nd
day of culture.

3. Results
3.1. Culture of 143B and hMSCs lines
The 143B and hMSCs lines cultured without any
contamination, and cells were observed to maintain
original morphology during expansion (Figures 1a and
1b).
3.2. GFP labeling and BMP2 transfection of hMSCs
All hMSCs used in this study was labeled with GFP for the
localization of the transplanted cells in the tissue. hMSCs
were observed directly under fluorescent microscopy at

3.3. ELISA measurement of BMP2 levels
The BMP2 levels in hMSCs and BMP2+hMSCs cultures
were ≤5.85 pg/mL and 23.4 ± 2 pg/mL, respectively, and
the difference between the two cultures was statistically
significant (p < 0.01).
The BMP2 level in 143B+hMSCs coculture was 17.55
± 11.7 and 11.7 ± 0.6 pg/mL in the 4th and 14th days,
respectively. The BMP2 level in 143B+BMP2+hMSCs
coculture was 40.96 ± 17.6 and 23,4 ± 0.6 pg/mL in the 4th
and 14th days, respectively, and the difference between the
two was statistically significant (p < 0.01) (Figure2).

Figure 1. The microphotographs of the cultures of the 143B cells, hMSCs and BMP+hMSCs. a. Morphology of cultured 143B cells. Scale
bar 20 µm. b. Morphology of cultured hMSC. Scale bar 20 µm. c. GFP staining of cultured hMSCs in the fluorescent microscopy. d. GFP
staining of cultured BMP2+hMSCs in the fluorescent microscopy.
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Figure 2. In vitro BMP2 protein levels (pg/mL: picograms per mililiter) and in vitro gene expression analysis. On the left side, the
secreted BMP2 level of hMSC and BMP2+hMSC was analyzed before and after the coculture with 143B cells. BMP2 secretion of hMSC
and BMP2+hMSC on the 4th day compared and BMP2 secretion increased approximately 4-fold (p < 0.01). BMP2 levels increased in
the measurements performed at the end of 4th and 14th days of cocultures (1: 1) with osteosarcoma 143B cell lines. On the right side,
comparison of the gene expression of osteogenic differentiation markers in BMP2+hMSC and hMSC in vitro. The expression of PF4,
COL1A1, OPN, BMP2, OCN and BMP4 were evaluated. ActB was used as the housekeeping gene in the analysis. The significance of the
results with respect to the control group was indicated by asterix (*) when p < 0.01.

3.4. In vitro gene expression analysis
The expressions of BMP2, BMP4, COL1A1, and OPN in
143B+BMP2+hMSCs coculture compared to 143B+hMSCs
coculture was 8-,5-, 2- and 5-fold more, respectively, while
OCN and PF4 expressions were 0.5-fold less (Figure2).
3.5. In vivo studies
In all mice except one, limping started on the 14th
day, and histopathological investigations revealed the
presence of tumoral mass around the knee joint, posterior
popliteal soft tissue, and proximal tibia. A tumoral
embolism in a popliteal lymphatic vessel and a focal lung
metastasis was detected in the mouse without limping.
Immunohistochemical studies could not be performed
in two mice, one from the control and the other from the
second group, as the size of their tumors were too small for
manipulation.
The tumor diameters ranged between 0.1 and 2.2 cm,
while the mean diameter was significantly greater in the
hMSCs group compared to controls (p < 0.01) (Figure 3a).
The tumoral necrosis was found to be significantly more in
the hMSCs group (p < 0.001) and BMP2+hMSCs group (p
< 0.05) when compared to controls (Figure 3b). Metastasis
(bilateral in 20, bilobal in 14) was present in 39 of the
mice (multiple in 26). The number of metastatic foci was
significantly lower in BMP2+hMSCs compared to hMSCs
group (p < 0.01) (Figure 3c).
The histopathological evaluations in all tumoral tissue
showed undifferentiated sarcoma morphology with very
high cellularity, extremely atypical spindle cells, extremely
high mitotic activity, and necrosis of varying degrees
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(Figure 4a). Focal differentiation characterized by minimal
osteoid production was present in only eight tumors. All
tumors were compatible with high-grade fibroblastic type
classical osteosarcoma. The immunohistochemical studies
revealed positive BMP2 expressions in all osteosarcoma
tissue, and no significant difference was observed among
groups (p > 0.05) (Figure 4b).
The expression of p27 in the BMP2+hMSCs group
was significantly lower than those of the other groups
(p > 0.05) (Figures 3d and 4c). We did not observe any
significant difference in Ki-67 and caspase-3 expressions
among groups (p > 0.05) (Figure 4d).
GFP expressions in hMSCs and BMP2+hMSCs groups
were significantly more compared to controls and BMP2
group (p < 0.01) (Figure 5). The relative expressions of
BMP2, BMP4, OCN, OPN, COL1A1, and PF4 were shown
for all groups (Figure 6). In the BMP2 group, there was
a significant 10-fold increase in BMP2, a 5-fold increase
in both BMP4 and OPN, and a 2-fold increase in PF4
when compared with the controls (p < 0.01). There was
a significant 9-fold increase in the relative expression of
BMP4 in the hMSCs group when compared to controls
(p < 0.01), while the expressions of BMP2, COL1A1, and
OCN reduced significantly 3- , 3- , and 2-fold, respectively
(p < 0.01). In the BMP2+hMSCs group, the BMP2
expression was significantly 10-fold more, while BMP4
was significantly 5-fold more compared to controls. The
expressions of OCN, COL1A1, and PF4 in BMP2+hMSCs
groups compared to controls were significantly increased
4- , 2- , and 80-fold, respectively (p < 0.01).

SARI et al. / Turk J Biol

Figure 3. a. The dimensions of tumor (milimeter). The dimensions of tumor in hMSC group were found significantly higher than control
group (*p < 0.01). There was no significant relation between the control group and BMP2+hMSC group. b. The extent of necrosis in
tumor tissue. The extent of necrosis in the tumor tissue were found significantly greater in hMSC and BMP2+hMSC groups than control
group (*p < 0.05). c. The number of metastatic foci. The number of metastatic foci were significantly lower in BMP2+hMSC group than
in hMSC group (*p < 0.01). d. p27 immunostaining of tumor tissues. p27 staining level was significantly lower in BMP2+hMSC group
than in hMSC group (*p < 0.05).

4. Discussion
The target-selective biotherapy has been the subject of
recent research. The duration of the biodelivery system
activity has been one of the obstacles for efficient cancer
biotherapy (Lee et al., 2019). The tumoral site with
inflammation and tissue remodeling is the preferential
location for MSCs. The pathotropic migratory properties
of MSCs make them potential tumor-targeted delivery
tools. The critical step for a successful engraftment into
the tumor tissue after transplantation of MSCs is the
homing (Becker and Riet, 2016). One of the determinants
of effective MSC homing is the route of administration.
Although intravenous administration is the most
commonly used route, a significant amount of hMSCs
could be trapped in the lungs as a result of the pulmonary
first-pass effect (Khakoo et al., 2006). On the other hand,
the intraarterial route due to procedural invasiveness and
the embolism risk has not been generally preferred (Qiao
et al., 2015). Although not commonly used as the systemic
vascular delivery, efficient homing after intraperitoneal
administration of hMSCs have been reported previously.
Targeted inhibition of OS growth and lung metastasis
in mice had been achieved by the intraperitoneal
administration of cytosine deaminase/5-fluorocytosine
transfected MSCs (NguyenThai et al., 2015).
The orthotopic xenograft murine OS model was
established using 143B OS cell line, known for its
aggressive and metastatic properties (Luu et al., 2005).

Histopathological studies confirmed the presence of
high-grade fibroblastic type classical OS consistent with
previous reports (Tian et al., 2019). The GFP expression
in hMSCs was significantly higher than that of unlabeled
hMSCs confirming successful GFP transfection of
hMSCs (p < 0.05). The GFP expressions in hMSCs and
BMP2+hMSCs were significantly higher than those of the
control and BMP2 groups in vivo (p < 0.05). The similar
GFP expression levels in cultures and tissues indicated an
efficient homing of hMSCs in the targeted OS tissue after
intraperitoneal administration and in line with previous
studies (NguyenThai et al., 2015).
The
MSC
behaviors
in
various
tumor
microenvironments are distinct. In one study,
osteoprotegerin transduced MSCs targeted to mice OS
reduced the tumor size (Qiao et al., 2015), while MSCs
educated with tumor-secreted extracellular vesicles
contributed to OS growth and metastasis in a murine
xenograft model in another study (Lagerweij et al., 2018).
Recently, discrepant research results on the impact of MSCs
on OS have been reported (Zheng et al., 2018). The growthpromoting or metastasis-inducing roles of MSCs were
found in some studies (Zheng et al., 2018); the suppression
of OS (Gauthaman et al., 2012) and Kaposi sarcoma
(Khakoo et al., 2006) were observed in others. BMPs that
also regulate cellular expansion and differentiation have
been studied for their effects on cancer (Thawani et al.,
2010). Despite the findings of higher tumoral expressions,
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Figure 4. The microphotographs of the morphological and immunohistochemical experiments. a. A microscopic focus showing minimal
differentiation of osteosarcoma cells characterized by osteoid matrix production (hematoxylin-eosin staining; ×400). b. Osteosarcoma
cells displaying diffuse cytoplasmic staining with BMP2 antibody, similar to the striated muscle bundles on the right lower corner of
the frame (immunohistochemistry staining; ×100). c. Osteosarcoma cells displaying score 12 nuclear and cytoplasmic staining patterns
with p27 (immunohistochemistry staining; ×100). d. 1 (+) staining intensity similar to bronchial epithelium with caspase-3 displayed in
a metastatic focus in lung tissue (Immune histochemistry staining; ×40).

i.e. BMP2 and BMP4 in high-grade OS, their use as a
treatment option in OS has been suggested. A recent study
demonstrated the promotion of OS cell migration and
invasion by BMP2 treatment, while no effect of BMP2 on
OS was demonstrated in another study (Tian et al., 2019).
However, rapid enzymatic degradation of BMP2 after
direct administration led to the search for identifying tools
for stable delivery (Tian et al., 2019).
The combined effect of BMP2 and hMSCs had been
suggested to be synergistic and more efficient in sustaining
and inducing the formation and differentiation of bone
tissue (Ishikawa et al., 2007). We observed that the BMP2
levels in the coculture, which initially increased, started
to decrease in ten days. The gradual decline in BMP2
levels might indicate that the effect of coculturing has
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not been steadily sustainable and rather faced the risk of
vanishing ultimately. One another possible explanation
of the decrease in the BMP2 levels in the 14th day of the
coculture might be because of transient transfection of
BMP2+hMSCs. Nevertheless, the 2-fold more levels on
the 14th culture day compared to precoculture values
might indicate the possibility of a synergistic effect of
BMP2 and hMSCs as reported previously (Ishikawa et al.,
2007). Interestingly, an investigation using OS cell lines
with high (143B) and low (MNNG-HOS-RFP) metastatic
potential demonstrated the enhancement of metastasis
by transfer of Ki-ras gene from 143B line in vivo (Tome
et al., 2009), giving rise to the question of whether gene
transfer between OS cells and MSCs could be a possibility
(Zheng et al., 2018). We suspect whether the increase in
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Figure 5. GFP expression in vivo. Screening of GFP expression in the tissue
after the transplantation of hMSCs and BMP2+hMSC. The GFP expression
could be detected in the samples above the orange line, where only the cell
transplanted groups (hMSC and BMP2+hMSC) were localized. No significant
GFP expression was measured in the control group and BMP2 groups.

Figure 6. Gene expression analyses in vivo. Gene expression analysis of tissues
transplanted with BMP2+hMSC. The expression of PF4, COL1A1, OPN,
BMP2, OCN and BMP4 were evaluated. BMP2+hMSC group, in which the
transplanted cells were cotransfected with BMP2 and GFP, was compared
to BMP2 group, hMSC group and the control group. The significance of the
results with respect to the control group was indicated by asterix (*) when p
< 0.01.

BMP2 in 143B+hMSCs coculture compared to hMSCs
culture might support the possibility of gene transfer or
just suggest the interaction of any potential undescribed
stimulative factors between the two cell lines.

The mean tumor size in the hMSCs group was
significantly greater than that of the controls (p < 0.01).
The extent of the tumoral necrotic area was found to be
significantly more in hMSCs (p < 0.001) and BMP2+hMSCs
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(p < 0.05) groups compared to the others. Additionally,
the number of metastatic foci was significantly lower in
the BMP2+hMSCs group compared to the hMSCs group
(p < 0.01). The histopathological results indicated that
hMSCs treatment caused a greater tumoral size and rapid
progression, as shown by more necrotic foci and metastasis;
thus, supporting studies that reported a link between
tumoral promotion and metastasis in OS and hMSCs
(Lagerweij et al., 2018). The BMP2 immunostaining
revealed positive reactivity in all study groups, indicating
BMP2 gene expression in OS cells. The expression of Ki67, which was suggested as a prognostic marker due to its
association with tumor proliferation and lung metastasis in
OS, showed no difference among study groups as expected
from the established murine model of OS using 143B cell
line, known for its aggressive and metastatic properties
(Gallagher et al., 2012). In some studies, BMP2 treatmentrelated OS growth inhibition was associated with a
lower number of Ki-67 positive cells (Xiong et al., 2018).
Although statistically not significant, the Ki-67 expression
tended to be the lowest in the BMP2 group compared to
others, giving possible support to previous results (Xiong
et al., 2018). Alternatively, the amount of hMSCs in the
tumor environment might be more than the amount that
could be compensated by the released amount of BMP2
for a sufficient suppression of the metastatic process. The
cytoplasmic expression of the apoptotic protein, caspase-3,
was positive in all study groups. Lower levels of caspase-3
were associated with higher grade canine OS, while the
administration of canine BMSCs and BMP2 in a murine
model of OS resulted in increased expressions of caspase-3
(Reg et al., 2013). When the treated mice compared with
the controls, a tendency towards lower expressions of
caspase-3 was observed in BMP2 and/or hMSCs groups,
suggesting a potential regulatory effect of BMP2 and
hMSCs on the balance of cell proliferation/apoptosis
cycle favoring apoptosis. We consider that this might
be just possible for tumor microenvironment, not for
physiological conditions. Recently, the p27 mislocalization
by interaction and activation of PAK1-mediated actin
polymerization was shown to promote OS metastasis (Chen
et al., 2020). Immunohistochemical studies revealed the
mislocalization of p27 in tissue sections from all groups;
however, the p27 staining in the BMP2+hMSCs group
was significantly lower than those of others (p < 0.05).
Moreover, in vivo evaluations indicated that the number
of metastasis in the BMP2+hMSCs group was significantly
lower than that of the hMSCs group (p < 0.01). The current
results could be interpreted as a possible effect of BMP2
transfected hMSCs on the metastatic cascade at tissue level
and seemed to be in line with previous results (Chen et al.,
2020).
The interactions among OS and hMSCs were explored
by the degree of differentiation of tumoral cells using
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osteogenic markers like COL1A1,OPN, and OCN that
are sequentially expressed matching the temporal pattern
of osteoblastic differentiation (Edgar et al., 2007). The
failure to reach terminal osteogenic differentiation in
OS cells was demonstrated by lower levels of alkaline
phosphatase (ALP), Runx2, OSX, and OSP, while the
expressions of OPN and OCN were found indifferent to
the BMP2 stimulation (Luo et al., 2008). In other studies,
the use of modulators like miR148B or coculturing BMP2
transfected MSCs with Endothelial Progenitor Cells
were found to cause effective cell proliferation, BMP2
secretion, and better differentiation as demonstrated
by higher expressions of COL1A1 and OPN (Lee et al.,
2019). In addition to its role in osteogenic differentiation,
OPN has also been associated with the metastatic
process in OS, and increased expressions were observed
in lung metastasis. Recently, the adhesion of OS cells to
pulmonary epithelium has been shown to be mediated by
OPN (Villanueva et al., 2019). The antiproliferative action
of PF4 on MSCs had been demonstrated to be significantly
reduced during metastatic progression (Jian et al., 2017).
The low expressions of PF4 in OS tissue and high levels
in the circulation had been associated with poor outcome.
The in vitro analysis of 143B and BMP2+hMSCs
coculture demonstrated upregulations of BMP2, BMP4,
COL1A1, and OPN expressions. The most and least
increases were observed in BMP2 (8-fold) and COL1A1
(2-fold), respectively. On the other hand, OCN and PF4
expressions were reduced in half. These results suggest
that osteogenic differentiation had been achieved to an
extent; however, not fully completed, as shown by lack
of OCN upregulation. Another evidence of incomplete
differentiation was the lack of significant cell morphology
change and cytoplasmic mineral accumulation in
histopathological studies. Thus, the achieved osteogenic
differentiation was considered to be at the gene level that
was due to the constitutive expression of BMP2.
The in vivo gene expressions were compared between
four groups of mice. As expected, the greatest increase
in BMP2 expression (4-fold) was observed in the BMP2
group. On the other hand, the BMP4 expression (9-fold)
was the greatest in the hMSCs group. The same amount
of increase (5-fold) observed in BMP2 and BMP2+hMSCs
groups suggested the absence of a significant effect of
hMSCs in the presence of BMP2. When we examined the
expressions of BMP2 and BMP4 in four groups, a pattern
in treated mice groups appeared, indicating an inverse
expression level of BMP2 and BMP4 related to the BMP2
treatment in mice. When BMP2 increased in the BMP2+
groups, BMP4 decreased; when BMP4 increased in the
hMSCs group, BMP2 decreased. This might be due to the
temporal expression of BMP2 and BMP4 in the osteogenic
differentiation process, as reported (Edgar et al., 2007;
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Huang et al., 2007). Additionally, in the absence of BMP2,
hMSCs might tend to release BMP4 more, while the
presence of BMP2 in the microenvironment might cause
increased BMP2 expressions. The increase in COL1A1
expression was slight (0.1-fold) in the BMP2 group, while
a 2-fold increase was observed in the BMP2+hMSCs
group. On the contrary, a 0.5-fold reduction in COL1A1
was found in the hMSCs group. The results of COL1A1
expressions might be interpreted as the targeted efficiency
of BMP2 transduced hMSCs had been achieved in the
early phases of osteogenic differentiation in OS. The
hMSCs might have multimodal actions on differentiation
depending on the presence of osteogenic modulators in the
tumoral microenvironment. A 4-fold increase in OPN in
controls was suggestively due to the metastatic property of
the 143B cell line, as higher OPN expressions were recently
associated with pulmonary metastasis in OS (Villanueva
et al., 2019). In vitro increased expressions of OPN in
BMP2+hMSCs (5-fold) were found to be decreased (3fold) in vivo; it can be speculated that the in vitro results
reflected the differentiation achieved, while in vivo results
reflected the reduction in the metastatic process. The
5-fold increased expression in the BMP2 group compared
to 1-fold decreased expression in the hMSCs group
further suggested the reduction of the metastatic process
by BMP2 and augmentation by hMSCs. The expression
of OCN in vitro and in vivo differed greatly with 0.5-fold
reduction and 4-fold increase in BMP2+hMSCs culture
and group, respectively. This difference could be due to the
induction of differentiation in vivo by undefined potential
modulators, which were absent in the culture conditions.
Furthermore, in vivo experiments demonstrated strikingly
higher levels of PF4 expression (80-fold) in BMP2+hMSCs
compared to that of controls, suggesting a significant
increase in osteogenic differentiation as well as a reduction
in metastatic potential. Considering the gene expression
results in general from in vitro and in vivo studies, the
expressions of COL1A1 and BMP4 were the ones that
demonstrated the least change among other genes. It could
be speculated that BMP2 induction might contribute to
the differentiation process not in the beginning but at
some middle stage as COL1A1 and BMP4 are sequentially
expressed earlier than OPN and OCN, respectively.
Several limitations and strengths of the current
study should be acknowledged. In vivo experiments
were performed using immunocompromised mice,
and it should be noted that the sophisticated network

in a normal immune system would possibly interfere at
various checkpoints and in malignant processes during
OS formation, progression, and metastasis. Secondly, the
allowed time for in vitro and in vivo experiments might
potentially change the results; it would be rational to expect
more advanced differentiation given more time. Third, the
BMP2 level in the 143B cell culture did not measured. The
comments about the interactions between the 143B cells
and hMSCs or BMP2+hMSCs might be more precise and
accurate if the BMP2 levels in the native 143B cell culture
would be known. The conclusions driven from the results
of the cocultures of 143B and hMSCs or BMP2+hMSCs
might just be speculative or exaggerated.
Conclusively, this study, to the best of our knowledge,
is the first example of research on the effects of
intraperitoneally administered BMP2 transfected hMSCs
on human OS. The current results showed that the
intraperitoneal route could be efficiently used for targeting
hMSCs to the tumoral tissues for an effective gene delivery.
In this study, the effects of BMP2 transfected hMSCs on
human OS and metastasis were considered to be promising
for achieving osteogenic differentiation and reduced lung
metastasis.
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